Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AG-236

Small molecule · developed by Agios Pharmaceuticals

Phase 2/3 Most advanced trial
AGIO Developer
1 Registered trials

What is AG-236?

AG-236 is a drug studied in polycythemia vera.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Agios Pharmaceuticals, Inc. (AGIO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07859423 Phase 2/3 Polycythemia Vera Not yet recruiting AGIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Polycythemia Vera

More from Agios Pharmaceuticals

Mitapivat FDA approved AG-181 Phase 1 AG-636 Phase 1 AG-881 Phase 1 Tebapivat Phase 2

Follow AGIO, the company behind AG-236

See AGIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.